John W. Gillard

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

D. Riendeau, D. Denis, P. Prasit, 1992, Canadian journal of physiology and pharmacology.

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

P. Prasit, S. Charleson, J. Evans, 1992, Molecular pharmacology.

MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes.

H E Morton, C. Rouzer, A. Ford-hutchinson, 1990, The Journal of biological chemistry.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

D. Denis, C. Chan, S. Charleson, 1989, Canadian journal of physiology and pharmacology.

Photoaffinity labelling of the human platelet thromboxane A2/prostaglandin H2 receptor.

C. Yoakim, J. Rokach, J. Gillard, 1989, Biochimica et biophysica acta.

The unsymmetrical silaketal as a neutral, removable tether for effecting intramolecular diels-alder reactions.

M. Bernstein, J. Gillard, R. Glaser, 1991 .

Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of medicinal chemistry.